Empowered Funds LLC Acquires 12,775 Shares of Insmed, Inc. $INSM

Empowered Funds LLC lifted its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 32.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 51,986 shares of the biopharmaceutical company’s stock after purchasing an additional 12,775 shares during the period. Empowered Funds LLC’s holdings in Insmed were worth $8,501,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. CoreCap Advisors LLC bought a new stake in Insmed in the fourth quarter worth $27,000. Reflection Asset Management purchased a new position in shares of Insmed in the fourth quarter worth about $30,000. GraniteShares Advisors LLC purchased a new position in shares of Insmed in the fourth quarter worth about $30,000. CIBC Private Wealth Group LLC increased its holdings in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. Finally, Raiffeisen Bank International AG bought a new stake in shares of Insmed in the 4th quarter valued at about $32,000.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $235.00 price target on shares of Insmed in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research report on Friday, July 17th. Truist Financial dropped their price objective on Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. JPMorgan Chase & Co. cut their target price on shares of Insmed from $180.00 to $179.00 and set an “overweight” rating on the stock in a report on Monday, June 8th. Finally, Royal Bank Of Canada decreased their target price on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $209.35.

Insmed Trading Down 2.8%

NASDAQ INSM opened at $98.60 on Friday. The stock has a market cap of $21.37 billion, a P/E ratio of -17.15 and a beta of 0.78. Insmed, Inc. has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The stock has a 50 day simple moving average of $104.68 and a two-hundred day simple moving average of $131.02. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same quarter in the prior year, the company earned ($1.42) earnings per share. The firm’s revenue for the quarter was up 229.7% on a year-over-year basis. On average, analysts forecast that Insmed, Inc. will post -2.43 earnings per share for the current year.

Insider Activity at Insmed

In related news, CEO William Lewis sold 21,398 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the transaction, the chief executive officer owned 258,917 shares in the company, valued at $26,751,304.44. The trade was a 7.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 6,149 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $108.47, for a total transaction of $666,982.03. Following the completion of the sale, the insider owned 41,613 shares of the company’s stock, valued at $4,513,762.11. This trade represents a 12.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 54,590 shares of company stock valued at $5,793,738 over the last quarter. Company insiders own 2.10% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.